Design Therapeutics, Inc.
Financials
Valuation Metrics
Design Therapeutics, Inc.'s Market Cap is $634M. At end of 2025 it was $538M. Ranked #2623 of 3,118 in US market (top 84%), #1117 of 1,474 on NASDAQ (top 76%), #200 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $634M | US#2,623/3,118 Sec#200/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-71M | US—/3,118 Sec—/265 |
| Total Assets | $215M | US#2,969/3,118 Sec#240/265 |
| Net Assets | $202M | US#2,671/3,118 Sec#192/265 |
| Employees | 55 | US#2,696/3,118 Sec#208/265 |
| Value | ||
| P/B | 3.14x | US#1,882/3,118 Sec#105/265 |
| FCF Yield | -8.70% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -35.07% | US#2,591/3,118 Sec#124/265 |
| ROA | -32.91% | US#2,896/3,118 Sec#165/265 |
| Financial Health | ||
| Debt Ratio | 6.57% | US#58/3,118 Sec#28/265 |
| Total Debt | $2M | US#2,942/3,118 Sec#233/265 |
| FCF | $-55M | US#2,532/3,118 Sec#118/265 |
| Cash | $13M | US#2,927/3,118 Sec#260/265 |
| Current Ratio | 18.86x | US#120/3,118 Sec#27/265 |
| Performance | ||
| 1Y Return | 51.49% | US#351/3,118 Sec#63/265 |
| 1M Return | -17.75% | US#2,655/3,118 Sec#205/265 |
| From 52W High | -41.16% | US#2,274/3,118 Sec#161/265 |
| 1Y MDD | -38.96% | US#1,872/3,118 Sec#111/265 |
| Trading | ||
| Volume | 274,969 shares | US#2,635/3,118 Sec#249/265 |
| Trading Value | $3M | US#2,870/3,118 Sec#236/265 |
| Per Share | ||
| EPS | $-1.13 | US—/3,118 Sec—/265 |
| BPS | $3.23 | US#2,455/3,118 Sec#157/265 |
Company Info
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.